9/21/2025

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Boston Scientific Corporation is one of them Boston Scientific Corporation (NYSE:BSX) is emerging as a top AI-powered biotech stock by embedding artificial intelligence into its medical device portfolio, particularly in cardiology. Its AI strategy focuses on integrating advanced […]

Source: Yahoo

9/19/2025

Boston Scientific (BSX) is expected to provide a long-term organic revenue growth outlook at its upc

Source: Yahoo

9/18/2025

Boston Scientific Corporation (NYSE:BSX) is one of the best beginner stocks to buy, according to analysts. On September 11, analysts at Needham reiterated a ‘Buy’ rating on the stock and a $121 price target. The positive stance comes as the company plans to launch Bolt’s laser-based intravascular lithotripsy (IVL) system for peripheral use in late […]

Source: Yahoo

9/18/2025

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Source: Yahoo

9/18/2025

AVNS acquires Nexus Medical, adding its TKO connector to expand critical care offerings and drive immediate revenue and earnings growth.

Source: Yahoo

9/18/2025

ENTX posts positive PK data for its first oral GLP-2 therapy, signaling a potential breakthrough in short bowel syndrome treatment.

Source: Yahoo

9/17/2025

Cardinal Health opens a 350,000-square-foot Consumer Health Logistics Center in Ohio, strengthening its pharmaceutical supply chain and advancing its multiyear infrastructure expansion strategy.

Source: Yahoo

9/17/2025

GE HealthCare debuts AI-powered Voluson Performance ultrasound systems, enhancing women's health imaging with faster, smarter diagnostics.

Source: Yahoo

9/15/2025

Boston Scientific Corp. stock underperforms Monday when compared to competitors

Source: MarketWatch

9/15/2025

Here is how Boston Scientific (BSX) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.

Source: Yahoo

9/15/2025

Boston Scientific Corporation (NYSE:BSX) is one of the best defensive stocks to buy, according to Steve Cohen. On September 8, analysts at Oppenheimer upgraded the stock to an ‘Outperform’ from Perform and reiterated a $125 price target. The upgrade comes as Oppenheimer views the company as one of the best large-cap MedTech growth stories owing […]

Source: Yahoo

9/12/2025

Boston Scientific Corp. stock underperforms Friday when compared to competitors

Source: MarketWatch

9/12/2025

One-year data from Boston Scientific’s FARADISE registry demonstrated the strong efficacy of its Farapulse PFA system yet also revealed that some users are ablating more targets than necessary.

Source: Yahoo

9/11/2025

A major leadership change can quickly shift the conversation around a stock, and that is exactly what we have with Boston Scientific (BSX) this week. With news that Jeffrey B. Mirviss, Executive Vice President and President of Peripheral Interventions, will retire later this year, investors are left weighing what this transition means for one of the company's most important divisions. The timing is especially significant because this announcement comes just as Boston Scientific is in the...

Source: Yahoo

9/11/2025

This transaction will allow Elutia to advance its development and commercialisation efforts of its near-term pipeline without diluting shareholder value.

Source: Yahoo

9/10/2025

A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading.

Source: Yahoo

9/10/2025

The latest trading day saw Boston Scientific (BSX) settling at $105.23, representing a -2.65% change from its previous close.

Source: Yahoo

9/10/2025

AVNS's solid Q2 performance, strong product demand, and strategic transformation support growth amid tariff and FX headwinds.

Source: Yahoo

9/10/2025

Boston Scientific Corp. stock underperforms Wednesday when compared to competitors

Source: MarketWatch

9/10/2025

BTIG analysts estimate that Elutia’s Elupro and Medtronic’s TYRX are competing for a $600 million opportunity in the U.S. cardiac rhythm management sector.

Source: Yahoo